makes the selection on the basis of a growth of 57 per cent growth in revenue and 138 per cent in profit for the first half of this year. Considering the drug-maker’s closing price of N6.
09 at the last trading session, the stock is currently priced below its intrinsic value with a PE ratio of 6.66.NEM appears on the strength of its almost one-quarter expansion in sales and an increase of 29 per cent in profit at mid-year. The underwriter sees gross premium written rise to N25.5 billion and bottom-line to N4.1 billion come year end.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: